{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:50:38Z","timestamp":1793674238936,"version":"4.5.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001934","name":"American Academy of Dermatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001934","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaad.2021.05.056","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T11:28:19Z","timestamp":1623065299000},"page":"945-955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Guidelines of care for the management of actinic keratosis: Executive summary"],"prefix":"10.1016","volume":"85","author":[{"given":"Daniel B.","family":"Eisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam M.","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Dellavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther E.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Leffell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Peschin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Sligh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy A.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsy","family":"Frazer-Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E.","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2021.05.056_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CIA.S31930","article-title":"Optimal treatment of actinic keratoses","volume":"8","author":"Uhlenhake","year":"2013","journal-title":"Clin Interv Aging"},{"issue":"9","key":"10.1016\/j.jaad.2021.05.056_bib2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-4632.2007.03166.x","article-title":"Actinic keratosis","volume":"46","author":"Rossi","year":"2007","journal-title":"Int J Dermatol"},{"issue":"1, Part 2","key":"10.1016\/j.jaad.2021.05.056_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1067\/mjd.2000.103343","article-title":"Clinical presentation of actinic keratoses and squamous cell carcinoma","volume":"42","author":"Moy","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.05.056_bib4","first-page":"1099","article-title":"The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma","volume":"33","author":"Fuchs","year":"2007","journal-title":"Dermatol Surg"},{"issue":"8589","key":"10.1016\/j.jaad.2021.05.056_bib5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","article-title":"Malignant transformation of solar keratoses to squamous cell carcinoma","volume":"1","author":"Marks","year":"1988","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2021.05.056_bib6","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jaad.2012.09.053","article-title":"Pathobiology of actinic keratosis: Ultraviolet-dependent keratinocyte proliferation","volume":"68","author":"Berman","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.05.056_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/120347540200600301","article-title":"The majority of cutaneous squamous cell carcinomas arise in actinic keratoses","volume":"6","author":"Czarnecki","year":"2002","journal-title":"J Cutan Med Surg"},{"issue":"24","key":"10.1016\/j.jaad.2021.05.056_bib8","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/jnci\/djq442","article-title":"Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial","volume":"102","author":"Elmets","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"1 Pt 2","key":"10.1016\/j.jaad.2021.05.056_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2000.103339","article-title":"The risk of progression to invasive disease","volume":"42","author":"Glogau","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.05.056_bib10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1046\/j.1365-4362.1998.00467.x","article-title":"Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma","volume":"37","author":"Mittelbronn","year":"1998","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.05.056_bib11","first-page":"1462","article-title":"The paradigm shift in treating actinic keratosis: a comprehensive strategy","volume":"11","author":"Stockfleth","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2021.05.056_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2021.05.056","article-title":"Guidelines of care for the management of actinic keratosis","author":"Eisen","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.05.056_bib13","unstructured":"American Academy of Dermatology. Administrative regulation evidence-based clinical practice guidelines. Accessed November 1, 2019. https:\/\/server.aad.org\/forms\/Policies\/Uploads\/Members\/AR%20-%20Evidence-Based%20Clinical%20Practice%20Guidelines.pdf"},{"issue":"7","key":"10.1016\/j.jaad.2021.05.056_bib14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.jaad.2021.05.056_bib15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaad.2021.05.056_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jclinepi.2016.07.006","article-title":"Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group","volume":"80","author":"Guyatt","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaad.2021.05.056_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000366530","article-title":"Patients' perspectives on actinic keratosis","volume":"46","author":"Esmann","year":"2015","journal-title":"Curr Probl Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.05.056_bib18","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/bjc.1996.534","article-title":"Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study","volume":"74","author":"Harvey","year":"1996","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.jaad.2021.05.056_bib19","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical tretinoin Chemoprevention Trial","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2021.05.056_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/jdv.14092","article-title":"The importance of treating the field in actinic keratosis","volume":"31","author":"Stockfleth","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.056_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2133.2007.07942.x","article-title":"Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head","volume":"157","author":"Alomar","year":"2007","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1440-0960.2003.00003.x","article-title":"Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial","volume":"44","author":"Chen","year":"2003","journal-title":"Australas J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-2133.2009.09260.x","article-title":"Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial","volume":"161","author":"Gebauer","year":"2009","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles","volume":"62","author":"Hanke","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.05.056_bib25","first-page":"165","article-title":"Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream","volume":"10","author":"Hanke","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.05.056_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","article-title":"Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head","volume":"57","author":"Jorizzo","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.05.056_bib27","first-page":"1101","article-title":"A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses","volume":"9","author":"Jorizzo","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.05.056_bib29","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.05.056_bib30","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/archderm.138.11.1498","article-title":"A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses","volume":"138","author":"Stockfleth","year":"2002","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles","volume":"62","author":"Swanson","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology","volume":"51","author":"Szeimies","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.056_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","article-title":"Topical diclofenac in hyaluronan gel for the treatment of solar keratoses","volume":"44","author":"Gebauer","year":"2003","journal-title":"Australas J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1440-0960.1997.tb01693.x","article-title":"Topical diclofenac\/hyaluronic acid gel in the treatment of solar keratoses","volume":"38","author":"McEwan","year":"1997","journal-title":"Australas J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.056_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel","volume":"146","author":"Rivers","year":"2002","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.05.056_bib36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses","volume":"40","author":"Wolf","year":"2001","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.05.056_bib37","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/bjd.12847","article-title":"Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: a randomized clinical trial","volume":"170","author":"Zane","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.056_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2011.10613.x","article-title":"Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo","volume":"166","author":"Dirschka","year":"2012","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/bjd.12158","article-title":"Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis","volume":"168","author":"Dirschka","year":"2013","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib40","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bjd.14498","volume":"175","author":"Reinhold","year":"2016","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.05.056_bib41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2133.2010.09873.x","article-title":"Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study","volume":"163","author":"Szeimies","year":"2010","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.05.056_bib42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1600-0625.2008.00770.x","article-title":"Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch","volume":"18","author":"Hauschild","year":"2009","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2021.05.056_bib43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pdpdt.2018.10.010","article-title":"Conventional versus daylight photodynamic therapy for actinic keratosis: a randomized and prospective study in China","volume":"24","author":"Zhu","year":"2018","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"5","key":"10.1016\/j.jaad.2021.05.056_bib44","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/bjd.15272","article-title":"Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolaevulinic acid photodynamic therapy for treating multiple actinic keratosis","volume":"176","author":"Holzer","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.056_bib45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1067\/mjd.2001.114288","article-title":"Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light","volume":"45","author":"Jeffes","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.05.056_bib46","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/DSS.0000000000000630","article-title":"Randomized vehicle-controlled study of short drug incubation aminolevulinic acid photodynamic therapy for actinic keratoses of the face or scalp","volume":"42","author":"Pariser","year":"2016","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.056_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archderm.140.1.41","article-title":"Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: Investigator-blinded, phase 3, multicenter trials","volume":"140","author":"Piacquadio","year":"2004","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.05.056_bib48","first-page":"1483","volume":"11","author":"Schmieder","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib49","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/dsu.12462","article-title":"Novel photodynamic therapy does not prevent new skin cancers - randomized controlled trial","volume":"40","author":"Dixon","year":"2014","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.jaad.2021.05.056_bib50","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1365-2133.2009.09040.x","article-title":"Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies","volume":"160","author":"Hauschild","year":"2009","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.05.056_bib51","first-page":"255","article-title":"Efficacy of cryosurgery and 5-fluorouracil cream 0.5% combination therapy for the treatment of actinic keratosis","volume":"94","author":"Hoover","year":"2014","journal-title":"Cutis"},{"issue":"2","key":"10.1016\/j.jaad.2021.05.056_bib52","first-page":"36","article-title":"An investigator-initiated study to assess the safety and efficacy of imiquimod 3.75% cream when used after cryotherapy in the treatment of hypertrophic actinic keratoses on dorsal hands and forearms","volume":"6","author":"Goldenberg","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.05.056_bib53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2310\/7750.2007.00033","article-title":"Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses","volume":"11","author":"Tan","year":"2007","journal-title":"J Cutan Med Surg"},{"issue":"7","key":"10.1016\/j.jaad.2021.05.056_bib54","first-page":"669","article-title":"Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery","volume":"7","author":"Berlin","year":"2008","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.056_bib55","first-page":"35","article-title":"Treatment of actinic keratoses with sequential use of photodynamic therapy and imiquimod 5% cream","volume":"8","author":"Shaffelburg","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.056_bib56","first-page":"54","article-title":"Comparison of the efficacy of cryotherapy and 0.1% acnalen gel vs. cryotherapy and placebo in the treatment of actinic keratoses","volume":"28","author":"Azimi","year":"2012","journal-title":"Pak J Med Sci"},{"issue":"16","key":"10.1016\/j.jaad.2021.05.056_bib57","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJM199310143291602","article-title":"Reduction of solar keratoses by regular sunscreen use","volume":"329","author":"Thompson","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib58","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/archderm.139.4.451","article-title":"A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses","volume":"139","author":"Darlington","year":"2003","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.05.056_bib59","first-page":"335","article-title":"Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis","volume":"70","author":"Jorizzo","year":"2002","journal-title":"Cutis"},{"issue":"7","key":"10.1016\/j.jaad.2021.05.056_bib60","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archderm.140.7.813","article-title":"Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial","volume":"140","author":"Jorizzo","year":"2004","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.05.056_bib61","first-page":"133","article-title":"One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study","volume":"5","author":"Jorizzo","year":"2006","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.05.056_bib62","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamadermatol.2015.0502","article-title":"Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial","volume":"151","author":"Pomerantz","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.05.056_bib63","first-page":"22","article-title":"Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks","volume":"70","author":"Weiss","year":"2002","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.056_bib64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1440-0960.2008.00497.x","article-title":"PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study","volume":"50","author":"Siller","year":"2009","journal-title":"Australas J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.05.056_bib65","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaad.2009.01.008","article-title":"Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis","volume":"60","author":"Anderson","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.05.056_bib66","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jaad.2021.05.056_bib67","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/jdv.13211","article-title":"A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body","volume":"29","author":"Pellacani","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2021.05.056_bib68","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/bjd.14222","article-title":"Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0 015% gel: a randomized, controlled 12-month study","volume":"174","author":"Garbe","year":"2016","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.056_bib69","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2015.11.034","article-title":"Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): a randomized clinical trial","volume":"74","author":"Erlendsson","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.05.056_bib70","first-page":"432","article-title":"Assessment of efficacy and irritation of ingenol mebutate gel 0.015% used with or without dimethicone lotion for treatment of actinic keratosis on the face","volume":"16","author":"Jim On","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.05.056_bib71","first-page":"438","article-title":"Safety and efficacy of escalating doses of ingenol mebutate for field treatment of actinic keratosis on the full face, full balding scalp, or chest","volume":"16","author":"Hanke","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2021.05.056_bib72","author":"Pharma"},{"issue":"12","key":"10.1016\/j.jaad.2021.05.056_bib73","first-page":"1432","article-title":"A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes","volume":"10","author":"Foley","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.05.056_bib74","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/09546630310012118","article-title":"A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study","volume":"14","author":"Freeman","year":"2003","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.056_bib75","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cryobiol.2014.06.006","article-title":"Liquid nitrogen for the treatment of actinic keratosis: a longitudinal assessment","volume":"69","author":"Ianhez","year":"2014","journal-title":"Cryobiology"},{"issue":"5","key":"10.1016\/j.jaad.2021.05.056_bib76","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0190-9622(82)70143-4","article-title":"Cryosurgery cure rate of actinic keratoses","volume":"7","author":"Lubritz","year":"1982","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.05.056_bib77","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1067\/mjd.2002.119649","article-title":"Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study","volume":"47","author":"Szeimies","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.05.056_bib78","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-4632.2004.02056.x","article-title":"A prospective study of the use of cryosurgery for the treatment of actinic keratoses","volume":"43","author":"Thai","year":"2004","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.056_bib79","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI89820","article-title":"Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy","volume":"127","author":"Cunningham","year":"2017","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jaad.2021.05.056_bib80","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1540-9740.2007.06174.x","article-title":"Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant recipients","volume":"6","author":"Herman","year":"2007","journal-title":"Skinmed"},{"issue":"9","key":"10.1016\/j.jaad.2021.05.056_bib81","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11912-019-0831-1","article-title":"Cutaneous squamous cell carcinoma in immunosuppressed patients","volume":"21","author":"Tam","year":"2019","journal-title":"Curr Oncol Rep"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221010975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221010975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:59:48Z","timestamp":1759273188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221010975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0190962221010975"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.05.056","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines of care for the management of actinic keratosis: Executive summary","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.05.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.02.082","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}